Page 6 - Sarah Oconnell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesAustin murtaghSarah oconnellAkero therapeutics incExchange commissionAkero therapeuticsSouth sanPrivate securities litigation reform actAnnual reportQuarterly report

Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

22% and 24% of patients experienced at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 36, compared to 14% for placebo 4% of patients in each EFX dose group.

United statesSarah oconnellAndrew chengPa fibroscanStephen harrisonAustin murtaghAkero therapeutics incPinnacle clinical researchExchange commissionLiver biopsy analysis setNon invasive markersChange from baselineFull analysisSerum markersConference callSouth san

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Investor webcast on Tuesday, October 10 at 8:00 a.m. ET to present clinical dataSOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 Akero Therapeutics, Inc. , a clinical-stage company developing.

United statesAustin murtaghSarah oconnellExchange commissionAkero therapeutics incSouth sanPrivate securities litigation reform actAnnual reportQuarterly report

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSarah oconnellAustin murtaghAkero therapeutics incExchange commissionPresent resultsInvestigating efruxiferminCompensated cirrhosis dueSouth sanPrivate securities litigation reform actAnnual reportQuarterly report

Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet

As previously reported, the study met its primary endpoint of improvement in liver fibrosis without worsening of NASH at week 24, and key secondary endpoints including NASH resolution without worsening

United statesAustin murtaghSarah oconnellKitty yaleExchange commissionAkero therapeutics incLancet gastroenterologySouth sanPrivate securities litigation reform actAnnual reportQuarterly report